Published : 05 Mar 2019

---

Our new Korean client has developed E. coli Monophosphoryl Lipid A, a novel adjuvant. This is directly produced in genetically engineered E. coli and has the similar structure as MPLA from salmonella, Synthetic MPLA(GLA).

On account of Aagami’s expertise and strengths in the US, our Korean client has given us this assignment to find licensing partners for their differentiated offering.

Their E. coli Monophosphoryl Lipid A is a great boon for all companies particularly in vaccine development or manufacturing, cancer immunotherapy, Alzheimer immunotherapy, immune response control therapeutics and antibody production.

We feel that they have a great technology with clear advantages such as better characteristics, higher yield, simpler, faster and lower cost of manufacturing as compared to competition (very few).

We look forward to establishing long-term partnerships soon with Biopharma companies in the US.